Early RSV prevention offers economic benefits
USA-based MedImmune, which is owned by Anglo-Swedish drug major AstraZeneca (Marketletters passim), says that a recent analysis indicates that prevention of severe lower respiratory tract infection by respiratory syncytial virus in high-risk infants has considerable economic benefits in the long term.
Researchers at the West Virginia School of Medicine compared the cost of providing MedIummune's RSV drug Synagis (palivizumab) to premature babies with the estimated expense of the treatment of chronic disorders caused by the virus. The authors said that, while more evidence is needed to substantiate the link between MedIummne's product and subsequent reductions in persistent wheezing, early prevention of RSV infection offers considerable cost savings.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze